Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Nasdaq  >  Mylan N.V.    MYL   NL0011031208

MYLAN N.V.

(MYL)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsPress ReleasesOfficial PublicationsSector news

Mylan N : Drugmakers Mylan, Pfizer delay merger due to coronavirus outbreak

share with twitter share with LinkedIn share with facebook
share via e-mail
03/26/2020 | 06:27am EDT
FILE PHOTO: Logo of Mylan Laboratories, a company primarily engaged in the commercialization of generic drugs is pictured in Merignac near Bordeaux

Drugmaker Mylan NV's merger with Pfizer Inc's off-patent branded drug unit, Upjohn, will now close in the second half of this year, the companies said on Thursday, blaming the coronavirus pandemic for the delay.

Due to restrictions on large gatherings, the general meeting of shareholders to approve certain matters for the deal to go through has been postponed to June 30, Mylan said.

There were no other changes to previously announced terms or plans pertaining t
o the deal, previously expected to close in mid-2020, the companies said. (https://reut.rs/2Jfcelr)

The merger, which will bring blockbuster treatments Viagra and Lipitor from Pfizer under one umbrella with Mylan's EpiPen, is part of years-long effort by Pfizer to split into three parts - innovative medicines, lower margin off-patent drugs facing generic competition and consumer healthcare.

The combined company is expected to have 2020 revenue of $19 billion (16 billion pounds) to $20 billion.

Shares of both Pfizer and Mylan were down about 1% premarket.

(Reporting by Trisha Roy in Bengaluru; Editing by Shinjini Ganguli)

share with twitter share with LinkedIn share with facebook
share via e-mail
Latest news on MYLAN N.V.
03/30MYLAN N : offers concessions to address EU concerns about Pfizer deal
RE
03/27Mylan, Lupin Get Positive CHMP Opinion for Enbrel Biosimilar
DJ
03/27MYLAN N : and Lupin Announce Positive CHMP Opinion for Nepexto®, Biosimilar Etan..
PR
03/26GLOBAL MARKETS LIVE: Occidental Petroleum's saving plan, Mylan-Pfizer merger ..
03/26MYLAN N : Drugmakers Mylan, Pfizer delay merger due to coronavirus outbreak
RE
03/26MYLAN N : Drugmakers Mylan, Pfizer delay merger due to coronavirus outbreak
RE
03/26MYLAN N : Pfizer Say Upjohn Deal Closing Delayed to 2nd Half
DJ
03/25MYLAN N : Announces Additional Efforts to Support Response to the COVID-19 Pande..
PR
03/25MYLAN N : Statement Regarding India Manufacturing Facilities
PU
03/19MYLAN N : Ramps Up U.S. Manufacturing of Hydroxychloroquine Sulfate Tablets to M..
PR
More news
Financials (USD)
Sales 2020 11 933 M
EBIT 2020 3 244 M
Net income 2020 879 M
Debt 2020 9 235 M
Yield 2020 0,75%
P/E ratio 2020 8,45x
P/E ratio 2021 5,98x
EV / Sales2020 1,42x
EV / Sales2021 1,26x
Capitalization 7 696 M
Chart MYLAN N.V.
Duration : Period :
Mylan N.V. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends MYLAN N.V.
Short TermMid-TermLong Term
TrendsBearishBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 20
Average target price 23,53  $
Last Close Price 14,91  $
Spread / Highest target 94,5%
Spread / Average Target 57,8%
Spread / Lowest Target 14,0%
EPS Revisions
Managers
NameTitle
Heather M. Bresch Chief Executive Officer & Executive Director
Rajiv Malik President & Executive Director
Robert J. Coury Executive Chairman
Kenneth Scott Parks Chief Financial Officer
Andrea B. Miller Head-Global Research & Development
Sector and Competitors
1st jan.Capitalization (M$)
MYLAN N.V.-29.05%7 696
JOHNSON & JOHNSON-10.10%345 705
ROCHE HOLDING AG1.53%277 060
MERCK & CO., INC-18.86%195 141
NOVARTIS-14.15%187 703
PFIZER, INC.-18.96%181 075